Prostamax

Overview

Prostamax is a Khavinson-series 'peptide bioregulator' associated with the synthetic tetrapeptide Lys-Glu-Asp-Pro (KEDP), positioned as a short-peptide analog of bovine prostate extracts (in the same Russian product family as Prostatilen / Vitaprost). It is marketed on the Russian/Ukrainian grey market as a dietary peptide for prostate support; not an FDA-approved drug and not a substitute for evaluated BPH or prostatitis therapies. Research-use only in the US.

Mechanism of Action

Khavinson-group studies report that Prostamax partially relaxes nucleosomal 30-nm chromatin fiber, activates nucleolar organizer regions (NORs), and de-heterochromatinizes pericentromeric regions in lymphocytes, with claimed tissue-tropic effects on prostate cells. Mechanistic claims are confined to the Khavinson lab and have not been independently reproduced in Western andrology literature.

Research Summary

Evidence base is single-lab (Khavinson, Lezhava, and St. Petersburg collaborators) plus a broader Russian tradition of bovine prostate-extract peptides (Prostatilen/Vitaprost) used for BPH and chronic prostatitis. No FDA-registered trials and no human PK/toxicology data have been published for Prostamax itself.

Dosing Information

Reported Side Effects

• Injection site reactions
• Rare hypersensitivity

Research References

• Khavinson, Lezhava, Malinin — Effects of short peptides on lymphocyte chromatin in senile subjects (includes Prostamax, Bull Exp Biol Med) (2004)
• Meskhi et al. — The influence of the peptide bioregulator prostamax on heterochromatin of human lymphocytes in situ (Biofizika, Russian) (2004)
• Kuzmenko et al. — Bioregulatory peptides (Vitaprost, bovine prostate) in men with BPH and chronic prostatitis (Urologiia, Russian; related product class, not Prostamax itself) (2021)